A phase II trial observed that the use of high-dose metformin in mCRPC reduced PSA secretion and delayed the progression of prostate cancer [27].A cohort study based on a prostate cancer population showed that patients with hyperlipidemia may have prolonged survival with metformin and statins while undergoing radiotherapy [28]. This evidence concerns the gene KLK3 and prostate cancer.